Biotechnology

OncoC4 Announces First Patient Dosing in Phase 1 Clinical Trial of ONC-783 for the Treatment of Advanced Solid Tumors

— ONC-783 is the first-and-only clinical-stage T-cell engager targeting a cancer-specific glycoform of CD24 (neoCD24) — — Subcutaneous formulation designed to provide gradual systemic exposure, potentially mitigating CRS risk — ROCKVILLE, Md., Aug. 17, 2026 /PRNewswire/ -- OncoC4 Inc., a late c...

2026-08-17 20:00 3680

Kelun-Biotech Announces 2026 Interim Results

CHENGDU, China, Aug. 17, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", Stock Code: 6990.HK) announces its unaudited consolidated results for the period ended 30 June 2026 (the "Reporting Period"). Key information is as follows: * Re...

2026-08-17 19:18 4422

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

* Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages * Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is ...

2026-08-17 12:34 1832

New Study Confirms Capsugel® Enprotect® Capsules Deliver Robust Gastric Integrity Under Both Fasted and Fed Conditions

SEOUL, South Korea, Aug. 14, 2026 /PRNewswire/ -- Enteric capsules are widely used to protect acid-sensitive compounds and to delay drug release until intestinal entry. However, evidence supporting their gastric integrity under physiologically relevant fed-state conditions remains limited, as mos...

2026-08-17 11:45 2233

IASO Biotechnology Announces Acquisition of Singapore-Based Cell Therapy Company MediSix Therapeutics

NANJING, China and SINGAPORE, Aug. 14, 2026 /PRNewswire/ -- IASO Biotechnology ("IASO Bio) today announced the completion of its acquisition of MediSix Therapeutics ("MediSix"), a Singapore-based immune cell engineering and cell therapy company. This acquisition marks a step in IASO Bio's global...

2026-08-14 20:20 6772

SK bioscience Advances Development of Next-Generation Infectious Disease Prevention Platform with Global Phase 1b CTA Submission for RSV Preventive Antibody Candidate

* Phase 1b study will evaluate safety and pharmacokinetics of RSM01 in approximately 80 infants aged 2 weeks to 8 months * Company expands its global portfolio beyond vaccines into antibody-based preventive technologies * Growing global R&D network strengthens capabilities in next-generation...

2026-08-14 20:00 3815

ArkBio's RSV Antiviral Drug Ziresovir Receives FDA Approval for Phase II Clinical Trial

SHANGHAI, Aug. 14, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has approved ziresovir (AK0529) for a phase II clinical trial in the severely ill RSV infected infant patients, including the ones in pediat...

2026-08-14 18:18 2403

/DISREGARD RELEASE: IASO Bio/

We are advised by IASO Bio that journalists and other readers should disregard the news release, IASO Biotechnology Announces Acquisition of Singapore-Based Cell Therapy Company MediSix Therapeutics, issued 13-Aug-2026 over PR Newswire, as the release contained erroneous information. ...

2026-08-14 13:30 4015

Innorna Nominated for 2026 Prix Galien USA Best Startup Award

HONG KONG SAR, China and SHENZHEN, China and CAMBRIDGE, Mass., Aug. 13, 2026 /PRNewswire/ -- Innorna, a clinical-stage biotech company advancing RNA medicines, today announced that it has been nominated for the2026 Prix Galien USA Best Startup Award. Innorna was shortlisted in the Best Startup c...

2026-08-13 22:00 2864

Mervyn's Petcare Marks One Year at Magnify Incubator on UCLA campus with Launch of Second Feline Supplement on Amazon

SEOUL, South Korea, Aug. 13, 2026 /PRNewswire/ -- Ari's Purrfect Omega+Multivitamin Lickable Supplement expands the Feline First product line as Yuyu Pharma's U.S. pet subsidiary approaches a full year of growth at Magnify on UCLA campus. Mervyn's Petcare, ...

2026-08-13 21:00 2854

Axtria to Build Industry's Largest Pharma-Specific AI Engineering Team, Scaling to 1,000 by December 2026

NEW DELHI, Aug. 13, 2026 /PRNewswire/ -- Axtria Inc. ,  a global leader in AI-first data analytics solutions for the life sciences industry, today announced plans to expand itsFo...

2026-08-13 20:15 2905

Accro Bioscience to Present Phase Ib Data of AC-101, an Oral Selective RIPK2 Inhibitor, for Moderate-to-Severe UC at UEG Week 2026 in Barcelona

NEW YORK and SUZHOU, China, Aug. 13, 2026 /PRNewswire/ -- Accro Bioscience, a clinical-stage biotechnology company pioneering the development of novel therapeutics for immune mediated diseases, today announced that it will present efficacy and safety results from a Phase 1b proof-of-concept study...

2026-08-13 19:00 2425

Nobel Heroes Day 2026 - AI For Science Summit (AFSS) Launches in Singapore This October

Focusing on AI for Science: Nobel Laureates and Global Capital Explore the Frontiers of Scientific Innovation SINGAPORE, Aug. 12, 2026 /PRNewswire/ -- Nobel Heroes Day - AI For Science Summit (AFSS),co-hosted by Laureates City Holdings Limited and Symbiosis Science , will take place from5 to 11 O...

2026-08-13 11:19 4509

ArkBio Announces China IND Approval for its Antiviral Drug-Fc Conjugate (AFC) Candidate AK0406 for Influenza Prophylaxis

SHANGHAI, Aug. 13, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the Investigational New Drug (IND) application for AK0406 injection, the company's first long-acting antiviral drug‑Fc conjugate (AFC) candidate for influenza prophylaxis, has been app...

2026-08-13 09:00 3586

Bringing K-Aesthetics to Australia: PharmaResearch Showcases REJURAN® at Aesthetics 2026

Following REJURAN®'s TGA approval in 2023, the company hosted scientific sessions and a clinical masterclass for Australian healthcare professionals. GANGNEUNG, South Korea, Aug. 13, 2026 /PRNewswire/ -- PharmaResearch, the biopharmaceutical company behind REJURAN®, recently participated in Aesth...

2026-08-13 08:00 4223

PanTRKare™ Officially Approved as the Companion Diagnostic for VELMARTO® (Eratrectinib)

NANJING, China, Aug. 12, 2026 /PRNewswire/ -- August 6, the NMPA granted approval to Geneseeq's PanTRKare™ NTRK1/2/3 Gene Fusion Detection Kit as a companion diagnostic for VELMARTO® (Eratrectinib), a next‑generation highly selective TRK inhibitor independently developed by Vcare PharmaTech. The ...

2026-08-12 22:00 2981

Insilico Medicine Nominates ISM0900, a Potent, AI-driven, Oral Lp(a) Inhibitor, as PCC for Management of Cardiovascular Risks

CAMBRIDGE, Mass., Aug. 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the nomination of ISM0900, a potent, AI-driven, highly selective, orally available small molecule inh...

2026-08-12 20:30 2073

Beyang Closes Oversubscribed $30 Million Series A Financing

Funding to accelerate the iteration of the proprietary AI-driven ExCEED platform and advance global clinical development of differentiated pipelines, including a second-generation Menin inhibitor and a novel ophthalmic therapy. CHENGDU, China, Aug. 12, 2026 /PRNewswire/ -- Beyang Therapeutics Co....

2026-08-12 17:38 2898

Beyang Closes Oversubscribed $30 Million Series A Financing

Funding to accelerate the iteration of the proprietary AI-driven ExCEED platform and advance global clinical development of differentiated pipelines, including a second-generation Menin inhibitor and a novel ophthalmic therapy. CHENGDU, China, Aug. 12, 2026 /PRNewswire/ -- Beyang Therapeutics Co....

2026-08-12 17:10 2925

BASF Agricultural Solutions invests in new Climate Center at its headquarters to strengthen research capabilities

* State-of-the-art research facility at Limburgerhof site responds to increasing regulatory and research demands * Purpose-built facility will enable controlled, reproducible ecotoxicology studies to support the registration of crop protection products worldwide * Investment supports company...

2026-08-12 15:00 5094
12345678 ... 354